Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5483654 | 0.99 | POLB (0.41) | SMN1; SMN2LMNAPOLBMEN1KMT2A | |
| SCHEMBL8952584 | 0.72 | POLB (0.33) | SMN1; SMN2LMNAPOLB | |
| Iodide SCHEMBL1609671 | 0.69 | KMT2A (0.32) | KMT2A | |
| SCHEMBL8952654 | 0.63 | EPHX2 (0.31) | — | |
| SCHEMBL12473823 | 0.62 | KMT2A (0.32) | KMT2A | |
| SCHEMBL13413746 | 0.62 | LMNA (0.43) | SMN1; SMN2LMNAPOLBMEN1KMT2A | |
| SCHEMBL14357418 | 0.60 | PRMT5 (0.40) | SMN1; SMN2POLB | |
| SCHEMBL14357417 | 0.60 | PRMT5 (0.40) | SMN1; SMN2POLB | |
| Dyphylline SCHEMBL1816552 | 0.59 | LMNA (1.00) | SMN1; SMN2LMNAPOLB | |
| SCHEMBL4189383 | 0.59 | MAPT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648064-B2 | Metal complexes of N-heterocyclic carbenes | THE UNIVERSITY OF AKRON (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648064-B2 | Metal complexes of N-heterocyclic carbenes | THE UNIVERSITY OF AKRON (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103327816-A | Metal complexes of N-heterocyclic carbenes | UNIV AKRON | 2013-09-25 | — | — | CN | disclosed |
| US-8519146-B2 | Purine or imidazole and silver complexes; therapeutic, antimicrobial, and antifungal compounds; urinary tract infections | THE UNIVERSITY OF AKRON (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519146-B2 | Purine or imidazole and silver complexes; therapeutic, antimicrobial, and antifungal compounds; urinary tract infections | THE UNIVERSITY OF AKRON (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | THE UNIVERSITY OF AKRON (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | THE UNIVERSITY OF AKRON (US) | 2011-04-14 | — | — | US | disclosed |
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIVERSITY OF AKRON | 2007-01-25 | — | — | US | disclosed |
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIVERSITY OF AKRON | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | MKI67, AHR, ARNT | SMN1; SMN2 3972/4885LMNA 4017/4885POLB 1845/4885 |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | NOD2, ARNT, FPR1 | SMN1; SMN2 4838/4885LMNA 4321/4885POLB 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.